<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232893</url>
  </required_header>
  <id_info>
    <org_study_id>TU100P2T3</org_study_id>
    <nct_id>NCT02232893</nct_id>
  </id_info>
  <brief_title>Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy</brief_title>
  <acronym>TU100P2T3</acronym>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled Trial of TU-100 in Patients Undergoing Laparoscopic Colectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tsumura USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tsumura USA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TU-100 is a gastrointestinal drug produced from the three botanical raw materials, Asian
      ginseng, Zanthoxylum fruit (Japanese pepper), and ginger, based on proprietary aqueous
      decoction and granulation technology. The aim of this study is to assess the effect of TU-100
      on abdominal discomfort during the 4 week postoperative period after straight, hand-assisted,
      or robot-assisted laparoscopic colectomy. Optimal efficacy parameters for subsequent outcome
      studies also will be explored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life after surgery based on Gastrointestinal Quality of Life Index (GIQLI) global score</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of gastrointestinal motility as measured by time to first defecation of normal stool from the end of surgery</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative GI symptoms based on GIQLI single item score and domain score</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative bowel habit and abdominal discomfort based on patient's diary</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major postoperative complications</measure>
    <time_frame>Up to 36 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Postoperative Ileus</condition>
  <arm_group>
    <arm_group_label>Daikenchuto (TU-100)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daikenchuto (TU-100)</intervention_name>
    <description>Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 32 days.</description>
    <arm_group_label>Daikenchuto (TU-100)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 32 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age

          -  Has a current diagnosis of colon cancer, diverticulitis, or benign colonic neoplasm

          -  Requires straight, hand-assisted, or robot-assisted laparoscopic colectomy

          -  Requires hospitalization for surgery and recovery

        Exclusion Criteria:

          -  Has been diagnosed with rectal cancer, advanced or metastatic colon cancer, Crohn
             disease, ulcerative colitis, or volvulus

          -  Requires resection of rectal lesion

          -  Has received or is scheduled to receive chemotherapy during the duration of the study

          -  Is a pregnant or lactating female

          -  Has diabetic neuropathy

          -  Has a history or presence of diabetic gastroparesis

          -  Has a compromised immune system, either from treatment with corticosteroids or other
             immunosuppressive agent within 2 weeks of surgery or from immunosuppressive disease
             (e.g., human immunodeficiency virus)

          -  Has any other serious condition that might adversely affect suitability for
             participation in this study, such as liver disorder (including alanine
             aminotransferase or aspartate aminotransferase level greater than 2.5 times the upper
             limit of normal), kidney disorders, heart failure, blood disorders, or metabolic
             disorders

          -  Has a history or presence of interstitial pneumonia

          -  Has a history of allergic reaction to ginseng, ginger or Zanthoxylum fruit (Japanese
             pepper)

          -  Plans to receive any abdominal irradiation

          -  Is clinically lactose intolerant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Jensen, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colon &amp; Rectal Surgery Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Site</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metairie Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burlington, MA Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coon Rapids Site</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burlington, VT Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <disposition_first_submitted>April 26, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 1, 2018</disposition_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Quality of Life Index (GIQLI)</keyword>
  <keyword>Abdominal Discomfort</keyword>
  <keyword>Abdominal Bloating</keyword>
  <keyword>Laparoscopic colectomy</keyword>
  <keyword>Postoperative ileus (POI)</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

